Pruritus in adult dermatomyositis

Shirani, Z.; Kucenic, Michael; Carroll, Christie L.; Fleischer, Alan B.; Feldman, Steven R.; Yosipovitch, Gil; Jorizzo, Joseph L.

doi:10.1111/j.1365-2230.2004.01510.x

Cited by 66 publications

(46 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bi- 191 opsy with PAS stain may also be used to confirm the diagnosis [29] . Dermatomyositis Dermatomyositis has been linked to pruritus in up to 94% of diagnosed patients [33] . Other scalp manifestations that may be present are erythema, atrophy, scales, and diffuse non-scarring alopecia [34] ( Fig.…”

Section: Red Scalp Syndromementioning

confidence: 99%

Scalp Itch: A Systematic Review

Vázquez-Herrera

Sharma

Aleid

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

ated with a desire to scratch [1] . Just like skin pruritus, its etiology may be of dermatological or non-dermatological origin. It is common for the dermatologist to encounter patients with no evident cause of scalp pruritus, making it a distressing situation for both the clinician and the patient. The aim of this paper is to review the clinical signs of the most common causes of scalp itch and other less common causes that must be considered in a systematic approach to scalp pruritus. Materials and MethodsWe performed a MEDLINE search through PubMed (1975PubMed ( -2017, using the terms scalp itch and scalp pruritus and included clinical trials, review articles, case series, and case reports to search for the causes of scalp itch. PathophysiologyAlthough various pathogenic etiologies contribute to scalp pruritus, the scalp itself has distinct neuroanatomy and vasculature, specific neuromediators and corresponding receptors, as well as the presence of scalp sebum and microflora, which are all properties that may explain its tendency to be implicated in patients who complain of itch. Keywords Scalp · Itch · Pruritus · Seborrheic dermatitis · Contact dermatitis · Anxiety · Lichen planopilaris · Lice · Pediculosis · Psoriasis · Trichoscopy AbstractScalp itch is a frequent complaint in the dermatological setting. It is common for the dermatologist to encounter patients with no evident cause of scalp pruritus, making it a distressing situation for both the clinician and the patient. The aim of this paper is to propose a systematic approach to scalp itch, which classifies scalp pruritus into two types: (1) with or (2) without dermatological lesions, and presence or absence of hair loss. Also, it is important to think first about the most common causes and then rule out other, less common etiologies. The acronym SCALLP and the five steps for scalp evaluation (listen, look, touch, magnify, and sample) are useful tools to keep in mind for an assertive approach in these patients.

show abstract

Section: Red Scalp Syndromementioning

confidence: 99%

Scalp Itch: A Systematic Review

Vázquez-Herrera

Sharma

Aleid

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

“…Dermatomyositis sine myositis has also been documented [2]. The cutaneous lesions usually precede the onset of weakness by 3 to 6 months, [6] however, Pearson [11] has described one case, with skin involvement for 13 years. It is known that DM has a bimodal age distribution: one peak occurs in children between 5-14 yr of age and a second, larger peak occurs between 45-64 yr of age [13,14].…”

Section: Discussionmentioning

confidence: 99%

“…Muscle disease may occur concurrently or it may precede the skin disease or it may follow the skin disease by weeks to years (Bohan 1975). Skin rash often precedes the onset of weakness by weeks to months [11]. Early in disease course, rash and muscle enzyme elevations may be the sole manifestations of DM [12].…”

Section: Discussionmentioning

confidence: 99%

Cutaneous manifestations of dermatomyositis in male patient: a rare report

Dhavalshankh¹,

Dhavalshankh²,

Masvekar³

2013

Our Dermatol Online

View full text Add to dashboard Cite

Introduction: Dermatomyositis is an idiopathic inflammatory myopathy. It is a systemic disorder that most frequently affects the skin and muscles, but may also affect the joints, the esophagus, the lungs, and, less commonly, the heart. Case report: It is presented with characteristic cutaneous findings like skin rash as well as progressive symmetrical proximal muscle weakness. Its prevalence rate is approximately one per 100,000 in the general population with a female to male predominance of about 2:1. Conclusion:We report a male patient with the classical features of dermatomyositis in whom cutaneous changes preceded muscle weakness.

show abstract

“…2 A), zlokalizowane są głównie na powierzchniach grzbietowo-bocznych stawów między-paliczkowych i stawów śródręczno-palcowych, mają barwę fiołkową, hiperkeratotyczną powierzchnię, z widoczną centralną atrofią [6]. Wśród niektórych badaczy panuje przekonanie, że nie są one wykwitami pierwotnymi, ale powstają wtórnie do drapania [7]. Objaw Gottrona (ryc.…”

Section: Zmiany Skórneunclassified

“…W badaniu ankietowym przeprowadzonym przez Shirani i wsp. [7] u 26 chorych z DM świąd raportowany był u ponad 80% respondentów. W skali VAS (0-100 pkt) jego nasilenie zostało ocenione na 44,6 pkt, z okresowymi zaostrzeniami do powyżej 60 pkt.…”

Section: Zmiany Skórneunclassified

Special papers Diagnostic and therapeutic advances in dermatomyositis

Samotij¹,

Szczęch²,

Reich³

2015

View full text Add to dashboard Cite

StreSzczenieZapalenie skórno-mięśniowe (dermatomyositis -DM) zalicza się do grupy tzw. idiopatycznych miopatii zapalnych (ang. idiopathic inflammatory myopathies -IIM). Schorzenie to ma podłoże autoimmunologiczne, cechuje się obecnością zmian skórnych i/lub objawami zapalenia mięśni. Wyróżnia się tzw. klasyczną postać DM, postać dziecięcą DM oraz paraneoplastyczną DM, DM indukowane lekami i DM bez zaję-cia mięśni. Ostatnio obserwuje się dynamiczny postęp w identyfikacji nowych autoprzeciwciał towarzyszących poszczególnym odmianom DM, w tym anty-TIF1, anty-NXP2, anty-SAE czy anty-MDA5. Prawdopodobnie w niedalekiej przyszłości przyczyni się on do zwiększenia częstości rozpoznawania DM i jego poszczególnych odmian, lepszej stratyfikacji pacjentów pod względem ryzyka zajęcia poszczególnych narządów wewnętrznych oraz wpłynie na całościową poprawę wyników leczenia. Obecnie glikokortykosteroidy są podstawą terapii DM, jednak wprowadzenie do lecznictwa szeregu nowych leków immunomodulujących i immunosupresyjnych, w tym leków biologicznych, wiąże się ze znaczącym zwiększeniem przeżywalności pacjentów z tą chorobą. W niniejszej pracy dokonano przeglądu piśmiennictwa na temat najnowszych trendów w diagnostyce i leczeniu DM. AbStrActDermatomyositis (DM) is one of the so-called idiopathic inflammatory myopathies (IIM). Dermatomyositis is an autoimmune disorder characterized by the presence of cutaneous lesions and/or symptoms of muscle involvement with the following variants: the "classic" variant of DM, juvenile DM, paraneoplastic DM, drug-induced DM and amyopathic DM. Dynamic discoveries of novel autoantibodies, including anti-TIF1, anti-NXP2, anti-SAE or anti-MDA5, related to certain DM variants, have been described in recent years. It seems that these antibodies will contribute to better recognition of DM and its particular variants, a better risk stratification for predicting internal organ involvement, and to a global improvement of treatment outcome. Corticosteroids remain the mainstay of DM therapy, but new immunomodulatory and immunosuppressive agents, including biologicals, resulted in a significant increase of the survival rate of DM patients. Here, we review the current literature data on DM with special emphasis on new trends in its diagnostics and treatment.

show abstract

Pruritus in adult dermatomyositis

Cited by 66 publications

References 20 publications

Scalp Itch: A Systematic Review

Scalp Itch: A Systematic Review

Cutaneous manifestations of dermatomyositis in male patient: a rare report

Special papers Diagnostic and therapeutic advances in dermatomyositis

Contact Info

Product

Resources

About